Royalty Pharma plc — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Pablo Legorreta (CEO) and Terrance Coyne (CFO) signed standard Sarbanes-Oxley Section 302 and 906 certifications on August 5, 2026 for the quarter ended June 30, 2026, certifying that the 10-Q contains no material untrue statements, that financial statements fairly present the company's condition and operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine SOX certification exhibits—boilerplate, required disclosure with no operational, financial, or strategic change disclosed.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.